November 1, 2011
Kunihiko Suzuki, an executive member of the JMA (Japan Medical Association) Board of Trustees, talked about next year’s NHI drug pricing reform in a recent interview with Jiho, Inc. Regarding the premium for new drug development and elimination of off-label...read more